XML 80 R31.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Organization and Significant Accounting Policies, Revenue Recognition (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | ---
Oct. 31, 2018 USD ($) PerformanceObligation | Feb. 28, 2017 USD ($) PerformanceObligation | May 31, 2015 USD ($) PerformanceObligation | Sep. 30, 2013 USD ($) PerformanceObligation | Dec. 31, 2012 USD ($) PerformanceObligation | Dec. 31, 2019 USD ($) | Sep. 30, 2019 USD ($) | Jun. 30, 2019 USD ($) | Dec. 31, 2018 USD ($) | Jun. 30, 2018 USD ($) Agreement | Sep. 30, 2017 USD ($) Target Payment | Jun. 30, 2015 USD ($) | Dec. 31, 2019 USD ($) PerformanceObligation Payment | Dec. 31, 2018 USD ($) | Dec. 31, 2017 USD ($) | Apr. 30, 2018 USD ($) PerformanceObligation
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of performance obligations at inception of contract | PerformanceObligation |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,122,599 | $ 599,674 | $ 514,179 |
Biogen [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of agreements | Agreement |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |
Licensing and Other Royalties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 17,205 | $ 14,755 | $ 7,474 |
2013 Strategic Neurology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  | $ (16,500) |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |
Number of separate performance obligations | PerformanceObligation |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  |  |  | $ 100,000 |  |  |  |  |  |  |  |  |  |  |  |
2013 Strategic Neurology [Member] | Licensing and Other Royalties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  | $ 35,000 |  |  |  |  |  |  |
AstraZeneca [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  | 30,000 |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | $ 31,000 | $ 10,000 |  |  |  |  |  |  |  |  |  |
Number of separate performance obligations | PerformanceObligation |  |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |
IONIS-FB-L for Complement-Mediated Diseases [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received | $ 75,000 |  |  |  |  |  |  |  | $ 75,000 |  |  |  |  |  |  |
Number of separate performance obligations | PerformanceObligation | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price | $ 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2018 Strategic Neurology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  | $ 375,000 |  |  |  |  |  |
Number of milestone payments achieved | Payment |  |  |  |  |  |  |  |  |  |  | 2 |  | 4 |  |  |
Milestone payments received and added to transaction price |  |  |  |  |  |  |  |  |  |  | $ 7,500 |  |  |  |  |
Number of new targets advanced | Target |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |
Number of separate performance obligations | PerformanceObligation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1
Transaction price |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 552,000
2012 Neurology [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 10,000 | $ 6,300 |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |  |
2012 Neurology [Member] | Licensing and Other Royalties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 45,000 |  |  |  |  |  |  |  |  |  |
Pfizer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | 246,000 |  |  |  |  |  |  |  |  |  |
Alnylam [Member] | Licensing and Other Royalties [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |
Bayer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |
Number of separate performance obligations | PerformanceObligation |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Bayer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  | $ 100,000 |  |  |  |  |  |  |  |  | $ 100,000 |  |  |  |
Number of separate performance obligations | PerformanceObligation |  |  | 3 |  |  |  |  |  |  |  |  |  |  |  |  |
Bayer [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue Recognition [Abstract] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  | $ 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Transaction price |  | $ 75,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition The number of agreements entered into with the collaboration partner. + References No definition available. + Details
Name: | ions_NumberOfAgreementsWithCollaborationPartner
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of milestone payments achieved during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfMilestonePaymentsAchieved
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of new targets advanced during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_NumberOfNewTargetsAdvanced
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of performance obligations at the inception of a contract. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfPerformanceObligationsAtInceptionOfContract
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of separate performance obligations under the collaboration agreement. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerNumberOfSeparatePerformanceObligations
Namespace Prefix: | ions_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of consideration the Company earned or is eligible to earn under the collaboration agreement, including any variable consideration. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPrice
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The additional amount of consideration the Company earned under the collaboration agreement that is added to the transaction price. + References No definition available. + Details
Name: | ions_RevenueFromContractWithCustomerTransactionPriceAdditions
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of upfront payments received during the period under the collaboration agreement. + References No definition available. + Details
Name: | ions_UpfrontPaymentReceived
Namespace Prefix: | ions_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_MajorCustomersAxis=ions_BiogenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=ions_LicensingAndOtherRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInSeptember2013WithBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithAstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2018WithRocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInApril2018WithBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInDecember2012WithBiogenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInOctober2019WithPfizerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMarch2004WithAlnylamPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementsAndLicensingAgreementsBayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementEnteredIntoInMay2015WithBayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ions_CollaborativeArrangementAndLicensingAgreementAmendedInFebruary2017WithBayerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |